The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Alpha-Antitrypsin Deficiency Treatment Market Research Report 2024
Synopsis
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The global Alpha- Antitrypsin Deficiency Treatment market was valued at US$ 1860.6 million in 2023 and is anticipated to reach US$ 3443.4 million by 2030, witnessing a CAGR of 9.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Alpha- Antitrypsin Deficiency Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha- Antitrypsin Deficiency Treatment.
Report Scope
The Alpha- Antitrypsin Deficiency Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Alpha- Antitrypsin Deficiency Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Alpha- Antitrypsin Deficiency Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Segment by Type
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Segment by Application
Clinic
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alpha- Antitrypsin Deficiency Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The global Alpha- Antitrypsin Deficiency Treatment market was valued at US$ 1860.6 million in 2023 and is anticipated to reach US$ 3443.4 million by 2030, witnessing a CAGR of 9.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Alpha- Antitrypsin Deficiency Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha- Antitrypsin Deficiency Treatment.
Report Scope
The Alpha- Antitrypsin Deficiency Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Alpha- Antitrypsin Deficiency Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Alpha- Antitrypsin Deficiency Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Segment by Type
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Segment by Application
Clinic
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alpha- Antitrypsin Deficiency Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CT-2009
1.2.3 POL-6014
1.2.4 ARO-AAT
1.2.5 ALNAAT-02
1.2.6 Others
1.3 Market by Application
1.3.1 Global Alpha- Antitrypsin Deficiency Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Perspective (2019-2030)
2.2 Alpha- Antitrypsin Deficiency Treatment Growth Trends by Region
2.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Region (2019-2024)
2.2.3 Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2025-2030)
2.3 Alpha- Antitrypsin Deficiency Treatment Market Dynamics
2.3.1 Alpha- Antitrypsin Deficiency Treatment Industry Trends
2.3.2 Alpha- Antitrypsin Deficiency Treatment Market Drivers
2.3.3 Alpha- Antitrypsin Deficiency Treatment Market Challenges
2.3.4 Alpha- Antitrypsin Deficiency Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Revenue
3.1.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Revenue (2019-2024)
3.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue
3.4 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio
3.4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha- Antitrypsin Deficiency Treatment Revenue in 2023
3.5 Alpha- Antitrypsin Deficiency Treatment Key Players Head office and Area Served
3.6 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
3.7 Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Alpha- Antitrypsin Deficiency Treatment Breakdown Data by Type
4.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2019-2024)
4.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2025-2030)
5 Alpha- Antitrypsin Deficiency Treatment Breakdown Data by Application
5.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Application (2019-2024)
5.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2019-2030)
6.2 North America Alpha- Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2019-2024)
6.4 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2019-2030)
7.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2019-2024)
7.4 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size (2019-2030)
8.2 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size (2019-2030)
9.2 Latin America Alpha- Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2019-2024)
9.4 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size (2019-2030)
10.2 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Adverum Biotechnologies, Inc.
11.1.1 Adverum Biotechnologies, Inc. Company Detail
11.1.2 Adverum Biotechnologies, Inc. Business Overview
11.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.1.4 Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.1.5 Adverum Biotechnologies, Inc. Recent Development
11.2 Alnylam Pharmaceuticals, Inc.
11.2.1 Alnylam Pharmaceuticals, Inc. Company Detail
11.2.2 Alnylam Pharmaceuticals, Inc. Business Overview
11.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.2.4 Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.2.5 Alnylam Pharmaceuticals, Inc. Recent Development
11.3 Applied Genetic Technologies Corporation
11.3.1 Applied Genetic Technologies Corporation Company Detail
11.3.2 Applied Genetic Technologies Corporation Business Overview
11.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
11.3.4 Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.3.5 Applied Genetic Technologies Corporation Recent Development
11.4 Arrowhead Pharmaceuticals, Inc.
11.4.1 Arrowhead Pharmaceuticals, Inc. Company Detail
11.4.2 Arrowhead Pharmaceuticals, Inc. Business Overview
11.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.4.4 Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.4.5 Arrowhead Pharmaceuticals, Inc. Recent Development
11.5 Carolus Therapeutics, Inc.
11.5.1 Carolus Therapeutics, Inc. Company Detail
11.5.2 Carolus Therapeutics, Inc. Business Overview
11.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.5.4 Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.5.5 Carolus Therapeutics, Inc. Recent Development
11.6 Cevec Pharmaceuticals GmbH
11.6.1 Cevec Pharmaceuticals GmbH Company Detail
11.6.2 Cevec Pharmaceuticals GmbH Business Overview
11.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Introduction
11.6.4 Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.6.5 Cevec Pharmaceuticals GmbH Recent Development
11.7 Dicerna Pharmaceuticals, Inc.
11.7.1 Dicerna Pharmaceuticals, Inc. Company Detail
11.7.2 Dicerna Pharmaceuticals, Inc. Business Overview
11.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.7.4 Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.7.5 Dicerna Pharmaceuticals, Inc. Recent Development
11.8 Digna Biotech, S.L.
11.8.1 Digna Biotech, S.L. Company Detail
11.8.2 Digna Biotech, S.L. Business Overview
11.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Introduction
11.8.4 Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.8.5 Digna Biotech, S.L. Recent Development
11.9 Editas Medicine, Inc.
11.9.1 Editas Medicine, Inc. Company Detail
11.9.2 Editas Medicine, Inc. Business Overview
11.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.9.4 Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.9.5 Editas Medicine, Inc. Recent Development
11.10 Grifols, S.A.
11.10.1 Grifols, S.A. Company Detail
11.10.2 Grifols, S.A. Business Overview
11.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Introduction
11.10.4 Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.10.5 Grifols, S.A. Recent Development
11.11 Inhibrx
11.11.1 Inhibrx Company Detail
11.11.2 Inhibrx Business Overview
11.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Introduction
11.11.4 Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.11.5 Inhibrx Recent Development
11.12 Intellia Therapeutics, Inc.
11.12.1 Intellia Therapeutics, Inc. Company Detail
11.12.2 Intellia Therapeutics, Inc. Business Overview
11.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.12.4 Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.12.5 Intellia Therapeutics, Inc. Recent Development
11.13 International Stem Cell Corporation
11.13.1 International Stem Cell Corporation Company Detail
11.13.2 International Stem Cell Corporation Business Overview
11.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
11.13.4 International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.13.5 International Stem Cell Corporation Recent Development
11.14 Ionis Pharmaceuticals, Inc.
11.14.1 Ionis Pharmaceuticals, Inc. Company Detail
11.14.2 Ionis Pharmaceuticals, Inc. Business Overview
11.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.14.4 Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.14.5 Ionis Pharmaceuticals, Inc. Recent Development
11.15 Kamada Ltd.
11.15.1 Kamada Ltd. Company Detail
11.15.2 Kamada Ltd. Business Overview
11.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
11.15.4 Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.15.5 Kamada Ltd. Recent Development
11.16 Polyphor Ltd.
11.16.1 Polyphor Ltd. Company Detail
11.16.2 Polyphor Ltd. Business Overview
11.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
11.16.4 Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.16.5 Polyphor Ltd. Recent Development
11.17 ProMetic Life Sciences Inc.
11.17.1 ProMetic Life Sciences Inc. Company Detail
11.17.2 ProMetic Life Sciences Inc. Business Overview
11.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.17.4 ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.17.5 ProMetic Life Sciences Inc. Recent Development
11.18 rEVO Biologics, Inc.
11.18.1 rEVO Biologics, Inc. Company Detail
11.18.2 rEVO Biologics, Inc. Business Overview
11.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.18.4 rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.18.5 rEVO Biologics, Inc. Recent Development
11.19 Sangamo BioSciences, Inc.
11.19.1 Sangamo BioSciences, Inc. Company Detail
11.19.2 Sangamo BioSciences, Inc. Business Overview
11.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.19.4 Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2019-2024)
11.19.5 Sangamo BioSciences, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
